famotidine has been researched along with Cardiac Hypertrophy in 1 studies
Famotidine: A competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion.
Cardiac Hypertrophy: Enlargement of the HEART due to chamber HYPERTROPHY, an increase in wall thickness without an increase in the number of cells (MYOCYTES, CARDIAC). It is the result of increase in myocyte size, mitochondrial and myofibrillar mass, as well as changes in extracellular matrix.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Potnuri, AG | 1 |
| Allakonda, L | 1 |
| Appavoo, A | 1 |
| Saheera, S | 1 |
| Nair, RR | 1 |
1 other study available for famotidine and Cardiac Hypertrophy
| Article | Year |
|---|---|
Association of histamine with hypertension-induced cardiac remodeling and reduction of hypertrophy with the histamine-2-receptor antagonist famotidine compared with the beta-blocker metoprolol.
Topics: Adrenergic beta-1 Receptor Antagonists; Age Factors; Animals; Blood Pressure; Cardiomegaly; Famotidi | 2018 |